Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Recent & Breaking News (NDAQ:GILD)

U.S. Food and Drug Administration Approved 30% More Drugs in 2012

Marketwired February 6, 2013

Gilead Sciences Announces Fourth Quarter and Full Year 2012 Financial Results

Business Wire February 4, 2013

Free Research Report on Marathon Petroleum Corp., Gilead Sciences, Inc., Carnival Corp. and Avago Technologies Ltd.

Marketwired February 4, 2013

Emerging Growth Pharmaceutical Company Creates Gravitational Pull Towards Their Products

PR Newswire January 30, 2013

Gilead Sciences to Release Fourth Quarter and Year End 2012 Financial Results on Monday, February 4, 2013

Business Wire January 28, 2013

Gilead Initiates Phase 3 Clinical Program for Tenofovir Alafenamide, a Novel Low-Dose Prodrug for the Treatment of HIV

Business Wire January 24, 2013

The True Effect: Positive Findings - Research Report on Celgene Corporation and Gilead Sciences, Inc.

PR Newswire January 23, 2013

GILD, MFC, VRX and MCK Freshly Hit a New 52-Week High

Marketwired January 10, 2013

Perfect Trade Setups, How to Play GILD, CYCC, PGOL and REE

Marketwired January 8, 2013

Gilead Provides Update on Hepatitis C Development Programs

Business Wire January 7, 2013

MacroGenics and Gilead Sciences Enter Strategic Alliance to Develop and Commercialize Four DART(tm) Products

PR Newswire January 7, 2013

Gilead Sciences to Present at the 31st Annual JPMorgan Healthcare Conference on Monday, January 7

Business Wire January 4, 2013

Beware the value trap

Matt Stiles October 23, 2008